Gross Profit Analysis: Comparing Amgen Inc. and Bristol-Myers Squibb Company

Amgen vs. Bristol-Myers: A Decade of Gross Profit Growth

__timestampAmgen Inc.Bristol-Myers Squibb Company
Wednesday, January 1, 20141564100000011947000000
Thursday, January 1, 20151743500000012651000000
Friday, January 1, 20161882900000014481000000
Sunday, January 1, 20171878000000014710000000
Monday, January 1, 20181964600000016014000000
Tuesday, January 1, 20191900600000018067000000
Wednesday, January 1, 20201926500000030745000000
Friday, January 1, 20211952500000036445000000
Saturday, January 1, 20221991700000036022000000
Sunday, January 1, 20231977500000034313000000
Monday, January 1, 20242056600000036351000000
Loading chart...

Data in motion

Gross Profit Trends: Amgen Inc. vs. Bristol-Myers Squibb Company

In the ever-evolving pharmaceutical industry, understanding financial performance is crucial. This analysis compares the gross profit trends of two giants: Amgen Inc. and Bristol-Myers Squibb Company, from 2014 to 2023. Over this period, Amgen's gross profit grew steadily, peaking in 2022 with a 27% increase from 2014. Meanwhile, Bristol-Myers Squibb experienced a dramatic surge, especially between 2019 and 2021, where their gross profit nearly tripled, reflecting strategic acquisitions and product launches. By 2023, Bristol-Myers Squibb's gross profit was approximately 74% higher than Amgen's, highlighting their aggressive market expansion. This decade-long comparison underscores the dynamic nature of the pharmaceutical sector, where strategic decisions significantly impact financial outcomes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025